AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17180128 — intervention group
Group type: EXPERIMENTAL
Intervention: Test solution (compared to sham),
Number of subjects: 20
Study 15677431 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching to olanzapine (intervention)
Number of subjects: 0
Study 15677431 — intervention group
Group type: COMPARATOR
Intervention: Prolactin-elevating antipsychotics (control)
Number of subjects: 0
Study 11384820 — intervention group
Group type: EXPERIMENTAL
Intervention: individualized, comprehensive, home‐based cardiac rehabilitation
Number of subjects: 99
Study 9566570 — intervention group
Group type: EXPERIMENTAL
Intervention: N2O pneumoperitoneum
Number of subjects: 40
Study 9566570 — intervention group
Group type: COMPARATOR
Intervention: CO2 pneumoperitoneum
Number of subjects: 40
Study 7816967 — intervention group
Group type: EXPERIMENTAL
Intervention: Ts group (coal workers with pneumoconiosis)
Number of subjects: 80
Study 7816967 — intervention group
Group type: COMPARATOR
Intervention: Tn group (coal workers with normal pulmonary X‐rays)
Number of subjects: 80
Study 7816967 — intervention group
Group type: COMPARATOR
Intervention: HTn group (underground miners with normal pulmonary X‐rays)
Number of subjects: 80
Study 2973694 — intervention group
Group type: EXPERIMENTAL
Intervention: Yeast-derived recombinant hepatitis B vaccine
Number of subjects: 0
Study 2973694 — intervention group
Group type: COMPARATOR
Intervention: Plasma-derived hepatitis B vaccine
Number of subjects: 0
Study 29661486 — intervention group
Group type: EXPERIMENTAL
Intervention: Socially evaluated cold pressure test
Number of subjects: 80
Study 29661486 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 80
Study 28554451 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable bite-blocks
Number of subjects: 21
Study 28554451 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 21
Study 25042995 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide plus Aralia root bark extract (ARBE)
Number of subjects: 148
Study 25042995 — intervention group
Group type: COMPARATOR
Intervention: Glipizide alone
Number of subjects: 148
Study 25230741 — intervention group
Group type: EXPERIMENTAL
Intervention: Catechin-rich green tea (615 mg/350 ml)
Number of subjects: 22
Study 25230741 — intervention group
Group type: COMPARATOR
Intervention: Placebo (92 mg/350 ml)
Number of subjects: 22
Study 21136039 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPSV
Number of subjects: 200
Study 21136039 — intervention group
Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 200
Study 19524409 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation therapy (CRT)
Number of subjects: 85
Study 17179244 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG guidance for CVC placement
Number of subjects: 290
Study 17179244 — intervention group
Group type: COMPARATOR
Intervention: NO-ECG guidance for CVC placement
Number of subjects: 290
Study 15008650 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraversion
Number of subjects: 0
Study 15008650 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated positive affect items
Number of subjects: 0
Study 15008650 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis
Number of subjects: 0
Study 15008650 — intervention group
Group type: COMPARATOR
Intervention: Neutral conditions
Number of subjects: 0
Study 11703992 — intervention group
Group type: EXPERIMENTAL
Intervention: Azimilide 100 mg/day
Number of subjects: 1380
Study 11703992 — intervention group
Group type: EXPERIMENTAL
Intervention: Azimilide 125 mg/day
Number of subjects: 1380
Study 11703992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1380
Study 11703992 — intervention group
Group type: EXPERIMENTAL
Intervention: Azimilide (100 and 125 mg/day)
Number of subjects: 1380
Study 9627377 — intervention group
Group type: EXPERIMENTAL
Intervention: Tall oil phytosterols (21.2 mg/kg body weight/d)
Number of subjects: 22
Study 9627377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 9627377 — intervention group
Group type: EXPERIMENTAL
Intervention: Tall oil phytosterols
Number of subjects: 22
Study 7706079 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation hypnosis
Number of subjects: 12
Study 7706079 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic training
Number of subjects: 12
Study 7706079 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 12
Study 7706079 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term effects of autogenic training
Number of subjects: 12
Study 2778240 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone (20 mg three times daily)
Number of subjects: 13
Study 2778240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 366807 — intervention group
Group type: EXPERIMENTAL
Intervention: Faustan (diazepam)
Number of subjects: 340
Study 31871515 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS (Transcutaneous Electric Nerve Stimulation) for 20 minutes, frequency adjusted for VAS 1-5 (subgroup 1)
Number of subjects: 60
Study 31871515 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS (Transcutaneous Electric Nerve Stimulation) for 20 minutes, frequency adjusted for VAS 6-10 (subgroup 2)
Number of subjects: 60
Study 31871515 — intervention group
Group type: EXPERIMENTAL
Intervention: MENS (Microcurrent Nerve Stimulation) for 20 minutes, frequency adjusted for VAS 1-5 (subgroup 3)
Number of subjects: 60
Study 31871515 — intervention group
Group type: EXPERIMENTAL
Intervention: MENS (Microcurrent Nerve Stimulation) for 20 minutes, frequency adjusted for VAS 6-10 (subgroup 4)
Number of subjects: 60
Study 28251153 — intervention group
Group type: EXPERIMENTAL
Intervention: Parotid salivary glucose measurement in type 2DM patients
Number of subjects: 30
Study 28251153 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose measurement in type 2DM patients
Number of subjects: 30
Study 28251153 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed salivary glucose measurement in type 2DM patients
Number of subjects: 30
Study 25703478 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional pattern 30 ms
Number of subjects: 74
Study 25703478 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional pattern 100 ms
Number of subjects: 74
Study 25703478 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigated pattern 30 ms
Number of subjects: 74
Study 25703478 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigated pattern 100 ms
Number of subjects: 74
Study 25703478 — intervention group
Group type: EXPERIMENTAL
Intervention: Short pulse groups (30 ms)
Number of subjects: 74
Study 25703478 — intervention group
Group type: EXPERIMENTAL
Intervention: Long pulse groups (100 ms)
Number of subjects: 74
Study 25703478 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigated 100 ms
Number of subjects: 74
Study 25703478 — intervention group
Group type: COMPARATOR
Intervention: Conventional single-spot 100 ms
Number of subjects: 74
Study 25703478 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigated 30 ms
Number of subjects: 74
Study 25703478 — intervention group
Group type: COMPARATOR
Intervention: Conventional 30 ms
Number of subjects: 74
Study 25703478 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 ms groups
Number of subjects: 74
Study 25703478 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ms groups
Number of subjects: 74
Study 25703478 — intervention group
Group type: EXPERIMENTAL
Intervention: Both 30 ms groups
Number of subjects: 74
Study 25039412 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal endoscopy (TNE)
Number of subjects: 157
Study 25039412 — intervention group
Group type: COMPARATOR
Intervention: Standard oesophago-gastro-duodenoscopy (SOGD)
Number of subjects: 157
Study 21963936 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 gp120/NefTat vaccine with AS02A adjuvant
Number of subjects: 20
Study 21963936 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant alone or placebo
Number of subjects: 20
Study 19948275 — intervention group
Group type: EXPERIMENTAL
Intervention: Verteporfin photodynamic therapy (VPDT)
Number of subjects: 4043
Study 17519010 — intervention group
Group type: EXPERIMENTAL
Intervention: AQ+SP
Number of subjects: 287
Study 17519010 — intervention group
Group type: EXPERIMENTAL
Intervention: AQ+AS
Number of subjects: 287
Study 17519010 — intervention group
Group type: COMPARATOR
Intervention: CQ
Number of subjects: 287
Study 15907056 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% centbucridine in saline
Number of subjects: 99
Study 15907056 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% centbucridine in saline
Number of subjects: 99
Study 15907056 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% lignocaine in distilled water
Number of subjects: 99
Study 15907056 — intervention group
Group type: COMPARATOR
Intervention: Unanaesthetized control (one eye)
Number of subjects: 99
Study 11238754 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mL red wine
Number of subjects: 12
Study 11238754 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g fried onions
Number of subjects: 12
Study 11238754 — intervention group
Group type: EXPERIMENTAL
Intervention: 375 mL black tea
Number of subjects: 12
Study 9540173 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 45 mg
Number of subjects: 70
Study 9540173 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 60 mg
Number of subjects: 70
Study 9540173 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 90 mg
Number of subjects: 70
Study 8007079 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis with suggestions to enhance the DTH response to VZ antigen
Number of subjects: 24
Study 8007079 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis with suggestions to suppress the DTH response
Number of subjects: 24
Study 8007079 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis with suggestions for relaxation only
Number of subjects: 24
Study 8007079 — intervention group
Group type: COMPARATOR
Intervention: Skin testing without hypnosis
Number of subjects: 24
Study 2179802 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthrinse (0.12% chlorhexidine digluconate, 15 ml, three times a day)
Number of subjects: 70
Study 2179802 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine mouthrinse
Number of subjects: 70
Study 408116 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 100 mg iron as ferrous glycocoll sulphate in micropellets
Number of subjects: 105
Study 408116 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 50 mg iron as ferrous glycocoll sulphate in micropellets
Number of subjects: 105
Study 408116 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron preparation given at the end of breakfast
Number of subjects: 105
Study 408116 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting absorption measurement
Number of subjects: 105
Study 31580506 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) for 12 weeks
Number of subjects: 69
Study 31580506 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) with standard physical activity recommendations
Number of subjects: 69
Study 31433483 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First (HF) with Intensive Case Management (ICM)
Number of subjects: 1198
Study 31433483 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 1198
Study 28073036 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative oral carbohydrate solution 800mL the night before and 400mL 2h prior to operation
Number of subjects: 43
Study 28073036 — intervention group
Group type: COMPARATOR
Intervention: Fasting for 8h prior to operation
Number of subjects: 43
Study 28073036 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative oral carbohydrate solution
Number of subjects: 43
Study 25957793 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily lipid-based nutrient supplement
Number of subjects: 1009
Study 25957793 — intervention group
Group type: COMPARATOR
Intervention: Multiple micronutrients
Number of subjects: 1009
Study 25957793 — intervention group
Group type: COMPARATOR
Intervention: Iron and folic acid
Number of subjects: 1009
Study 23241869 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-port laparoscopic appendectomy (SPLA)
Number of subjects: 224
Study 23241869 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic appendectomy (CLA)
Number of subjects: 224
Study 21801246 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri supplementation during the last month of gestation and through the first year of life
Number of subjects: 161
Study 21801246 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of L. reuteri in stool in the first week of life
Number of subjects: 161
Study 21801246 — intervention group
Group type: EXPERIMENTAL
Intervention: High Th2/Th1 ratio (CCL22/CXCL10) at birth
Number of subjects: 161
Study 21801246 — intervention group
Group type: EXPERIMENTAL
Intervention: High Th1-associated chemokine levels
Number of subjects: 161
Study 19001543 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 13
Study 19001543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 16732009 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled human insulin (Exubera)
Number of subjects: 427
Study 16732009 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 427
Study 16736343 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative ultrasonographic mapping (PUSM)
Number of subjects: 70
Study 16736343 — intervention group
Group type: COMPARATOR
Intervention: Physical examination (PE)
Number of subjects: 70
Study 14753759 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assessment manual for quality dental practice with feedback on scores and references
Number of subjects: 0
Study 14753759 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assessment manual for quality dental practice with attendance at a continuing education course on Quality Improvement
Number of subjects: 0
Study 14753759 — intervention group
Group type: COMPARATOR
Intervention: Self-assessment manual for quality dental practice only
Number of subjects: 0
Study 14753759 — intervention group
Group type: COMPARATOR
Intervention: Self-assessment manual for quality dental practice only at 1 year
Number of subjects: 0
Study 10589362 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab in combination with methotrexate (MTX)
Number of subjects: 0
Study 10589362 — intervention group
Group type: COMPARATOR
Intervention: Infliximab alone
Number of subjects: 0
Study 10589362 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab with high-dose MTX
Number of subjects: 0
Study 10589362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8735175 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (dose 2 to 16 mg)
Number of subjects: 107
Study 8735175 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) (dose 25 to 50 mg)
Number of subjects: 107
Study 8735175 — intervention group
Group type: COMPARATOR
Intervention: Doxazosin and HCTZ
Number of subjects: 107
Study 1929337 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin-sulbactam (750 mg orally twice daily for 10 days)
Number of subjects: 101
Study 1929337 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin (2 g intramuscularly) and probenecid (1 g orally), followed by doxycycline (100 mg orally twice daily for 10 days)
Number of subjects: 101
Study 1929337 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin-sulbactam
Number of subjects: 101
Study 1929337 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin-doxycycline
Number of subjects: 101
Study 7142889 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctor's assessment method
Number of subjects: 298
Study 7142889 — intervention group
Group type: COMPARATOR
Intervention: Health visitor's assessment method
Number of subjects: 298
Study 29323932 — intervention group
Group type: EXPERIMENTAL
Intervention: BrAC 0.08 g/210 L
Number of subjects: 96
Study 29323932 — intervention group
Group type: EXPERIMENTAL
Intervention: BrAC 0.10 g/210 L
Number of subjects: 96
Study 29323932 — intervention group
Group type: COMPARATOR
Intervention: BrAC 0.00 g/210 L
Number of subjects: 96
Study 26354331 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians' choice therapy (standard chemo‐ or endocrine therapy) with or without additional HER2‐targeted therapy with lapatinib (DETECT III trial)
Number of subjects: 2000
Study 26354331 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus and standard endocrine therapy (DETECT IVa)
Number of subjects: 2000
Study 26354331 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin (DETECT IVb)
Number of subjects: 2000
Study 26354331 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual HER2-targeted therapy (trastuzumab plus pertuzumab) plus either endocrine or chemotherapy (DETECT V/CHEVENDO trial)
Number of subjects: 2000
Study 26098442 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic sensory testing (conditioned pain modulation, temporal summation) in patients with PTTN
Number of subjects: 54
Study 26098442 — intervention group
Group type: EXPERIMENTAL
Intervention: Static sensory testing in patients with PTTN
Number of subjects: 54
Study 26098442 — intervention group
Group type: COMPARATOR
Intervention: Dynamic sensory testing in controls
Number of subjects: 54
Study 23222084 — intervention group
Group type: EXPERIMENTAL
Intervention: Localized muscle endurance resistance training (leg press exercise) at 10-30% 1 repetition maximum, 1 set of 960-1,200 repetitions, for 12 weeks, 3 sessions per week.
Number of subjects: 11
Study 23222084 — intervention group
Group type: EXPERIMENTAL
Intervention: Localized muscle endurance resistance training (leg press exercise)
Number of subjects: 11
Study 23222084 — intervention group
Group type: COMPARATOR
Intervention: Control leg (not trained)
Number of subjects: 11
Study 23222084 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 11
Study 21103740 — intervention group
Group type: EXPERIMENTAL
Intervention: Epicardial ultrasonic ablation on the right atrium and endocardial ultrasonic ablation on the left atrium during valve procedure
Number of subjects: 44
Study 21103740 — intervention group
Group type: COMPARATOR
Intervention: Valve procedure without ultrasonic ablation
Number of subjects: 44
Study 18755361 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical treatment combining a vitamin D derivative and a strong glucocorticoid
Number of subjects: 0
Study 18755361 — intervention group
Group type: COMPARATOR
Intervention: Long-established pharmaceuticals (cignolin, tar preparations, glucocorticoids)
Number of subjects: 0
Study 18755361 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer topical agents (vitamin A and D derivatives)
Number of subjects: 0
Study 18755361 — intervention group
Group type: EXPERIMENTAL
Intervention: Agents directed at tumor necrosis factor alpha, Toll-like receptors, and neutrophils
Number of subjects: 0
Study 18755361 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovations in glucocorticoids and vitamin A and D derivatives
Number of subjects: 0
Study 16839841 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle modification intervention
Number of subjects: 58
Study 14501738 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose human chorionic gonadotropin (HCG)
Number of subjects: 101
Study 14501738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 11208399 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (3 million KIU intraoperatively)
Number of subjects: 54
Study 11208399 — intervention group
Group type: COMPARATOR
Intervention: Control (non-treated with aprotinin)
Number of subjects: 54
Study 11208399 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 54
Study 9120179 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin
Number of subjects: 200
Study 9120179 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral N-acetylcysteine
Number of subjects: 200
Study 9120179 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin plus oral N-acetylcysteine
Number of subjects: 200
Study 9120179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 8468108 — intervention group
Group type: EXPERIMENTAL
Intervention: ITF 282 (60 mg iron/day, 2 tablets)
Number of subjects: 1095
Study 8468108 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulphate (105 mg iron/day, 1 tablet)
Number of subjects: 1095
Study 8468108 — intervention group
Group type: EXPERIMENTAL
Intervention: ITF 282
Number of subjects: 1095
Study 8468108 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulphate
Number of subjects: 1095
Study 2931153 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy and education programme
Number of subjects: 0
Study 2931153 — intervention group
Group type: COMPARATOR
Intervention: Bed rest
Number of subjects: 0
Study 30217672 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab plus trastuzumab and chemotherapy
Number of subjects: 780
Study 30217672 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus trastuzumab and chemotherapy
Number of subjects: 780
Study 26473300 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide (500 mg twice daily)
Number of subjects: 195
Study 26473300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study 25527255 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive health literacy strategy including training healthcare providers and use of an interactive Diabetes Education Toolkit
Number of subjects: 800
Study 25527255 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive health literacy strategy
Number of subjects: 800
Study 25527255 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 800
Study 22791760 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH)
Number of subjects: 60
Study 20385380 — intervention group
Group type: EXPERIMENTAL
Intervention: Modifying dietary carbohydrate in weight loss
Number of subjects: 0
Study 20385380 — intervention group
Group type: EXPERIMENTAL
Intervention: Modifying dietary protein in weight loss
Number of subjects: 0
Study 18669454 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus capecitabine (GemCap)
Number of subjects: 319
Study 18669454 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine (Gem)
Number of subjects: 319